UK allows pre-implantation tissue typing
This article was originally published in Clinica
The Human Fertilisation and Embryology Authority (HFEA) has decided, "in principle", to allow tissue typing to be used in conjunction with preimplantation genetic diagnosis (PGD) for "severe genetic disease". The decision enables the selection of embryos that are not only free from a specific congenital disease but in which the blood from its umbilical cord might be used in the treatment of a sibling affected by the disease.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.